Lipoproteins as modulators of atherothrombosis: From endothelial function to primary and secondary coagulation

Vascular Pharmacology

Volumn 82, Issue , 2016, Pages 1-10

  Ouweneel, Amber B ^a   Van Eck, Miranda ^a  

^a LEIDEN UNIVERSITY   (Netherlands)

Author keywords

Atherothrombosis; Coagulation; Endothelial function; Lipoproteins; Platelets

Indexed keywords

ACTIVATED PROTEIN C; AGENTS AFFECTING LIPID METABOLISM; BLOOD CLOTTING FACTOR 7; CHOLESTEROL ESTER TRANSFER PROTEIN INHIBITOR; CHYLOMICRON; ENDOTHELIAL NITRIC OXIDE SYNTHASE; FIBRINOGEN; HIGH DENSITY LIPOPROTEIN; INTERMEDIATE DENSITY LIPOPROTEIN; LIPOPROTEIN; LIVER X RECEPTOR; LOW DENSITY LIPOPROTEIN; NITRIC OXIDE; PRO PROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9 INHIBITOR; PROSTACYCLIN; PROTHROMBIN; THROMBIN; THROMBOPLASTIN; UNCLASSIFIED DRUG; VERY LOW DENSITY LIPOPROTEIN; VON WILLEBRAND FACTOR; ANTICOAGULANT AGENT; ANTILIPEMIC AGENT; OXIDIZED LOW DENSITY LIPOPROTEIN;

ANTICOAGULATION; APOPTOSIS; ARTERY INJURY; ARTERY RUPTURE; ATHEROSCLEROSIS; BLOOD CLOTTING; CARDIOVASCULAR RISK; CELL DENSITY; CHOLESTEROL TRANSPORT; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INTERVENTION STUDY; LIPID METABOLISM; LIPOPROTEIN BLOOD LEVEL; LIPOPROTEIN METABOLISM; NONHUMAN; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; PLATELET REACTIVITY; PRIORITY JOURNAL; PROTEIN INDUCTION; REVIEW; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION; THROMBOCYTE VOLUME; THROMBOSIS; THROMBOSIS PREVENTION; ANIMAL; ATHEROSCLEROTIC PLAQUE; BLOOD; DRUG EFFECTS; ENDOTHELIUM CELL; METABOLISM; PATHOLOGY; RUPTURE; SIGNAL TRANSDUCTION; THROMBOCYTE;

ANIMALS; ANTICOAGULANTS; ATHEROSCLEROSIS; BLOOD COAGULATION; BLOOD PLATELETS; ENDOTHELIAL CELLS; HUMANS; HYPOLIPIDEMIC AGENTS; LIPOPROTEINS; LIPOPROTEINS, HDL; LIPOPROTEINS, LDL; LIPOPROTEINS, VLDL; PLAQUE, ATHEROSCLEROTIC; PLATELET AGGREGATION; RUPTURE, SPONTANEOUS; SIGNAL TRANSDUCTION; THROMBOSIS;

EID: 84949034266     PISSN: 15371891     EISSN: 18793649     Source Type: Journal    
DOI: 10.1016/j.vph.2015.10.009     Document Type: Review

References (179)

1. [1] Ross, R., Atherosclerosis — an inflammatory disease. N. Engl. J. Med. 340 (1999), 115–126, 10.1056/nejm199901143400207.
2. [2] Lippi, G., Franchini, M., Targher, G., Arterial thrombus formation in cardiovascular disease. Nat. Rev. Cardiol. 8 (2011), 502–512, 10.1038/nrcardio. 2011.91.
3. [3] Furie, B., Furie, B.C., Mechanisms of thrombus formation. N. Engl. J. Med. 359 (2008), 938–949, 10.1056/NEJMra0801082.
4. [4] Falk, E., Shah, P.K., Fuster, V., Coronary plaque disruption. Circulation 92 (1995), 657–671.
5. [5] Davies, M.J., Stability and instability: two faces of coronary atherosclerosis. The Paul Dudley White Lecture 1995. Circulation 94 (1996), 2013–2020.
6. [6] Buffon, A., Biasucci, L.M., Liuzzo, G., D'Onofrio, G., Crea, F., Maseri, A., Widespread coronary inflammation in unstable angina. N. Engl. J. Med. 346 (2002), 1845–1853.
7. [7] Crea, F., Liuzzo, G., Pathogenesis of acute coronary syndromes. J. Am. Coll. Cardiol. 61 (2013), 1–11, 10.1016/j.jacc.2012.07.064.
8. [8] Libby, P., Theroux, P., Pathophysiology of coronary artery disease. Circulation 111 (2005), 3481–3488, 10.1161/CIRCULATIONAHA.105.537878.
9. [9] Libby, P., Pasterkamp, G., Requiem for the “vulnerable plaque.”. Eur. Heart J., 2015, ehv349, 10.1093/eurheartj/ehv349.
10. [10] Underhill, H.R., Yuan, C., Zhao, X.-Q., Kraiss, L.W., Parker, D.L., Saam, T., et al. Effect of rosuvastatin therapy on carotid plaque morphology and composition in moderately hypercholesterolemic patients: a high-resolution magnetic resonance imaging trial. Am. Heart J. 155 (2008), 584.e1–584.e8, 10.1016/j.ahj.2007.11.018.
11. [11] Libby, P., How does lipid lowering prevent coronary events? New insights from human imaging trials. Eur. Heart J. 36 (2015), 472–474, 10.1093/eurheartj/ehu510.
12. [12] Libby, P., Mechanisms of acute coronary syndromes and their implications for therapy — NEJM. N. Engl. J. Med. 368 (2013), 2004–2013, 10.1056/NEJMra1216063.
13. [13] Hu, S., Jia, H., Vergallo, R., Abtahian, F., Tian, J., Soeda, T., et al. Plaque erosion : in vivo diagnosis and treatment guided by optical coherence tomography. JACC Cardiovasc Interv 7 (2014), e63–e64, 10.1016/j.jcin.2013.10.024.
14. [14] Braunwald, E., Coronary plaque erosion : recognition and management. JACC Cardiovasc Imaging 6 (2013), 288–289, 10.1016/j.jcmg.2013.01.003.
15. [15] Rye, K.A., Clay, M.a., Barter, P.J., Remodelling of high density lipoproteins by plasma factors. Atherosclerosis 145 (1999), 227–238, 10.1016/S0021-9150(99)00150-1.
16. [16] Annema, W., von Eckardstein, A., High-density lipoproteins. Multifunctional but vulnerable protections from atherosclerosis. Circ. J. 77 (2013), 2432–2448, 10.1253/circj.CJ-13-1025.
17. [17] Libby, P., Aikawa, M., Stabilization of atherosclerotic plaques: new mechanisms and clinical targets. Nat. Med. 8 (2002), 1257–1262, 10.1038/nm1102-1257.
18. [18] Gordon, D.J., Knoke, J., Probstfield, J.L., Superko, R., Tyroler, H.A., High-density lipoprotein cholesterol and coronary heart disease in hypercholesterolemic men: the lipid research clinics coronary primary prevention trial. Circulation 74 (1986), 1217–1225.
19. [19] Miller, N.E., Thelle, D.S., Forde, O.H., Mjos, O.D., The Tromso heart-study. High-density lipoprotein and coronary heart-disease: a prospective case–control study. Lancet (London, England) 1 (1977), 965–968.
20. [20] Gordon, T., Castelli, W.P., Hjortland, M.C., Kannel, W.B., Dawber, T.R., High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study Am J Med 62 (1977), 707–714.
21. [21] Miller, M., Seidler, A., Kwiterovich, P.O., Pearson, T.A., Long-term predictors of subsequent cardiovascular events with coronary artery disease and “desirable” levels of plasma total cholesterol. Circulation 86 (1992), 1165–1170.
22. [22] Di Angelantonio, E., Sarwar, N., Perry, P., Kaptoge, S., Ray, K.K., Thompson, A., et al. Major lipids, apolipoproteins, and risk of vascular disease. JAMA 302 (2009), 1993–2000, 10.1001/jama. 2009.1619.
23. [23] Moore, K.J., Sheedy, F.J., Fisher, E.A., Macrophages in atherosclerosis: a dynamic balance. Nat. Rev. Immunol. 13 (2013), 709–721, 10.1038/nri3520.
24. [24] Gordon, D.J., Probstfield, J.L., Garrison, R.J., Neaton, J.D., Castelli, W.P., Knoke, J.D., et al. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation 79 (1989), 8–15, 10.1161/01.CIR.79.1.8.
25. [25] Vaisar, T., Pennathur, S., Green, P.S., Gharib, S.a., Hoofnagle, A.N., Cheung, M.C., et al. Shotgun proteomics implicates protease inhibition and complement activation in the antiinflammatory properties of HDL. J. Clin. Invest., 117, 2007, 10.1172/JCI26206DS1.
26. [26] Dashty, M., Motazacker, M.M., Levels, J., de Vries, M., Mahmoudi, M., Peppelenbosch, M.P., et al. Proteome of human plasma very low-density lipoprotein and low-density lipoprotein exhibits a link with coagulation and lipid metabolism. Thromb. Haemost. 111 (2014), 518–530, 10.1160/TH13-02-0178.
27. [27] Rezaee, F., Casetta, B., Levels, J.H.M., Speijer, D., Meijers, J.C.M., Proteomic analysis of high-density lipoprotein. Proteomics 6 (2006), 721–730, 10.1002/pmic.200500191.
28. [28] Rosenson, R.S., Tangney, C.C., Antiatherothrombotic properties of statins: implications for cardiovascular event reduction. JAMA 279 (1998), 1643–1650.
29. [29] Maron, D.J., Fazio, S., Linton, M.F., Current perspectives on statins. Circulation 101 (2000), 207–213.
30. [30] Colli, S., Eligini, S., Lalli, M., Camera, M., Paoletti, R., Tremoli, E., Vastatins inhibit tissue factor in cultured human macrophages: a novel mechanism of protection against atherothrombosis. Arterioscler. Thromb. Vasc. Biol. 17 (1997), 265–272, 10.1161/01.ATV.17.2.265.
31. [31] Dangas, G., Smith, D.A., Unger, A.H., Shao, J.H., Meraj, P., Fier, C., et al. Pravastatin: an antithrombotic effect independent of the cholesterol-lowering effect. Thromb. Haemost. 83 (2000), 688–692.
32. [32] Fenton, J.W. 2nd, Shen, G.X., Minnear, F.L., Brezniak, D.V., Jeske, W.P., Walenga, J.M., et al. Statin drugs and dietary isoprenoids as antithrombotic agents. Hematol Oncol Clin North Am 14 (2000), 483–490 xi.
33. [33] Takemoto, M., Liao, J.K., Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors. Arterioscler. Thromb. Vasc. Biol. 21 (2001), 1712–1719, 10.1161/hq 1101.098486.
34. [34] Levine, G.N., Keaney, J.F.J., Vita, J.A., Cholesterol reduction in cardiovascular disease. Clinical benefits and possible mechanisms. N. Engl. J. Med. 332 (1995), 512–521, 10.1056/NEJM199502233320807.
35. [35] Vita, J.a., Endothelial function. Circulation 124 (2011), 906–913, 10.1161/CIRCULATIONAHA.111.078824.
36. [36] Suwaidi, J.a., Hamasaki, S., Higano, S.T., Nishimura, R.a., Holmes, D.R., Lerman, a., Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction. Circulation 101 (2000), 948–954, 10.1161/01.CIR.101.9.948.
37. [37] Schächinger, V., Britten, M.B., Zeiher, a.M., Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease. Circulation 101 (2000), 1899–1906, 10.1161/01.CIR.101.16.1899.
38. [38] Halcox, J.P.J., Schenke, W.H., Zalos, G., Mincemoyer, R., Prasad, a., Waclawiw, M.a., et al. Prognostic value of coronary vascular endothelial dysfunction. Circulation 106 (2002), 653–658, 10.1161/01.CIR.0000025404.78001.D8.
39. [39] Yeboah, J., Crouse, J.R., Hsu, F.-C., Burke, G.L., Herrington, D.M., Brachial flow-mediated dilation predicts incident cardiovascular events in older adults: the cardiovascular health study. Circulation 115 (2007), 2390–2397, 10.1161/CIRCULATIONAHA.106.678276.
40. [40] Gokce, N., Risk stratification for postoperative cardiovascular events via noninvasive assessment of endothelial function: a prospective study. Circulation 105 (2002), 1567–1572, 10.1161/01.CIR.0000012543.55874.47.
41. [41] Treasure, C.B., Klein, J.L., Weintraub, W.S., Talley, J.D., Stillabower, M.E., Kosinski, A.S., et al. Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease. N. Engl. J. Med. 332 (1995), 481–487, 10.1056/NEJM199502233320801.
42. [42] Modena, M.G., Bonetti, L., Coppi, F., Bursi, F., Rossi, R., Prognostic role of reversible endothelial dysfunction in hypertensive postmenopausal women. J. Am. Coll. Cardiol. 40 (2002), 505–510, 10.1016/S0735-1097(02)01976-9.
43. [43] Shaul, P.W., Regulation of endothelial nitric oxide synthase: location, location, location. Annu. Rev. Physiol. 64 (2002), 749–774, 10.1146/annurev.physiol.64.081501.155952.
44. [44] Shaul, P.W., Endothelial nitric oxide synthase, caveolae and the development of atherosclerosis. J. Physiol. 547 (2003), 21–33, 10.1113/jphysiol.2002.031534.
45. [45] Chang, W.J., Rothberg, K.G., Kamen, B.a., RGW, A., Lowering the cholesterol content of MA104 cells inhibits receptor-mediated transport of folate. J. Cell Biol. 118 (1992), 63–69, 10.1083/jcb.118.1.63.
46. [46] Blair, A., Shaul, P.W., Yuhanna, I.S., Conrad, P.a., Smart, E.J., Oxidized low density lipoprotein displaces endothelial nitric-oxide synthase (eNOS) from plasmalemmal caveolae and impairs eNOS activation. J Biol Chem 274 (1999), 32512–32519, 10.1074/jbc.274.45.32512.
47. [47] Uittenbogaard, a., Shaul, P.W., Yuhanna, I.S., Blair, a., Smart, E.J., High density lipoprotein prevents oxidized low density lipoprotein-induced inhibition of endothelial nitric-oxide synthase localization and activation in caveolae. J Biol Chem 275 (2000), 11278–11283, 10.1074/jbc.275.15.11278.
48. [48] Yuhanna, I.S., Zhu, Y., Cox, B.E., Hahner, L.D., Osborne-Lawrence, S., Lu, P., et al. High-density lipoprotein binding to scavenger receptor-BI activates endothelial nitric oxide synthase. Nat. Med. 7 (2001), 853–857, 10.1038/89986.
49. [49] Lambert, G., Sakai, N., Vaisman, B.L., Neufeld, E.B., Marteyn, B., Chan, C.-C., et al. Analysis of glomerulosclerosis and atherosclerosis in lecithin cholesterol acyltransferase-deficient mice. J Biol Chem 276 (2001), 15090–15098, 10.1074/jbc.M008466200.
50. [50] Brill, A., Yesilaltay, A., De Meyer, S.F., Kisucka, J., Fuchs, T.a., Kocher, O., et al. Extrahepatic high-density lipoprotein receptor SR-BI and apoA-I protect against deep vein thrombosis in mice. Arterioscler. Thromb. Vasc. Biol. 32 (2012), 1841–1847, 10.1161/ATVBAHA.112.252130.
51. [51] Moncada, S., Gryglewski, R., Bunting, S., Vane, J.R., An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation. Nature 263 (1976), 663–665, 10.1038/263663a0.
52. [52] Caughey, G.E., Cleland, L.G., Penglis, P.S., Gamble, J.R., James, M.J., Roles of cyclooxygenase (COX)-1 and COX-2 in prostanoid production by human endothelial cells: selective up-regulation of prostacyclin synthesis by COX-2. J. Immunol. 167 (2001), 2831–2838, 10.4049/jimmunol.167.5.2831.
53. [53] Fleisher, L.N., Tall, a.R., Witte, L.D., Miller, R.W., Cannon, P.J., Stimulation of arterial endothelial cell prostacyclin synthesis by high density lipoproteins. J Biol Chem 257 (1982), 6653–6655.
54. [54] Pomerantz, K.B., Fleisher, L.N., Tall, a.R., Cannon, P.J., Enrichment of endothelial cell arachidonate by lipid transfer from high density lipoproteins: relationship to prostaglandin I2 synthesis. J. Lipid Res. 26 (1985), 1269–1276.
55. [55] Myers, D.E., Huang, W.N., Larkins, R.G., Lipoprotein-induced prostacyclin production in endothelial cells and effects of lipoprotein modification. Am J Physiol 271 (1996), C1504–C1511.
56. [56] Cockerill, G.W., Saklatvala, J., Ridley, S.H., Yarwood, H., Miller, N.E., Oral, B., et al. High-density lipoproteins differentially modulate cytokine-induced expression of E-selectin and cyclooxygenase-2. Arterioscler. Thromb. Vasc. Biol. 19 (1999), 910–917, 10.1161/01.ATV.19.4.910.
57. [57] Norata, G.D., HDL3 induces cyclooxygenase-2 expression and prostacyclin release in human endothelial cells Via a p38 MAPK/CRE-dependent pathway: effects on COX-2/PGI-synthase coupling. Arterioscler. Thromb. Vasc. Biol. 24 (2004), 871–877, 10.1161/01.ATV.zhq0504.1403.
58. [58] Calabresi, L., High-density lipoproteins protect isolated rat hearts from ischemia–reperfusion injury by reducing cardiac tumor necrosis factor-alpha content and enhancing prostaglandin release. Circ. Res. 92 (2003), 330–337, 10.1161/01.RES.0000054201.60308.1A.
59. [59] Van Sickle, W.a., Wilcox, H.G., Malik, K.U., Nasjletti, a., High density lipoprotein-induced cardiac prostacyclin synthesis in vitro: relationship to cardiac arachidonate mobilization. J. Lipid Res. 27 (1986), 517–522.
60. [60] Reininger, A.J., Heijnen, H.F.G., Schumann, H., Specht, H.M., Schramm, W., Ruggeri, Z.M., Mechanism of platelet adhesion to von Willebrand factor and microparticle formation under high shear stress., 107, 2006, 3537–3545, 10.1182/blood-2005-02-0618.Supported.
61. [61] Davi, G., Romano, M., Mezzetti, a., Procopio, a., Iacobelli, S., Antidormi, T., et al. Increased levels of soluble P-selectin in hypercholesterolemic patients. Circulation 97 (1998), 953–957, 10.1161/01.CIR.97.10.953.
62. [62] Blann, A.D., Dobrotova, M., Kubisz, P., MC, N., von Willebrand factor, soluble P-selectin, tissue plasminogen activator and plasminogen activator inhibitor in atherosclerosis. Thromb. Haemost. 74 (1995), 626–630.
63. [63] Zitoun, D., Bara, L., Basdevant, A., Samama, M.M., Levels of factor VIIc associated with decreased tissue factor pathway inhibitor and increased plasminogen activator inhibitor-1 in dyslipidemias. Arterioscler. Thromb. Vasc. Biol. 16 (1996), 77–81.
64. [64] Kawaguchi, a., Miyao, Y., Noguchi, T., Nonogi, H., Yamagishi, M., Miyatake, K., et al. Intravascular free tissue factor pathway inhibitor is inversely correlated with HDL cholesterol and postheparin lipoprotein lipase but proportional to apolipoprotein A-II. Arterioscler. Thromb. Vasc. Biol. 20 (2000), 251–258, 10.1161/01.ATV.20.1.251.
65. [65] Paka, L., Kako, Y., Obunike, J.C., Pillarisetti, S., Endothelial production of heparan sulfate rich in biologically active heparin-like domains. Biochemistry 274 (1999), 4816–4823.
66. [66] De Agostini, a.I., Watkins, S.C., Slayter, H.S., Youssoufian, H., Rosenberg, R.D., Localization of anticoagulantly active heparan sulfate proteoglycans in vascular endothelium: antithrombin binding on cultured endothelial cells and perfused rat aorta. J. Cell Biol. 111 (1990), 1293–1304, 10.1083/jcb.111.3.1293.
67. [67] Pillarisetti, S., Paka, L., Sasaki, A., Vanni-reyes, T., Yin, B., Parthasarathy, N., et al. Endothelial cell heparanase modulation of lipoprotein. Biochemistry 272 (1997), 15753–15759.
68. [68] Pillarisetti, S., Paka, L., Obunike, J.C., Berglund, L., Goldberg, I.J., Subendothelial retention of lipoprotein (a). Evidence that reduced heparan sulfate promotes lipoprotein binding to subendothelial matrix. J. Clin. Invest. 100 (1997), 867–874, 10.1172/JCI119602.
69. [69] Durand, E., Scoazec, a., Lafont, a., Boddaert, J., Al Hajzen, a., Addad, F., et al. In vivo induction of endothelial apoptosis leads to vessel thrombosis and endothelial denudation: a clue to the understanding of the mechanisms of thrombotic plaque erosion. Circulation 109 (2004), 2503–2506, 10.1161/01.CIR.0000130172.62481.90.
70. [70] Bombeli, T., Schwartz, B.R., Harlan, J.M., Endothelial cells undergoing apoptosis become proadhesive for nonactivated platelets. Blood 93 (1999), 3831–3838.
71. [71] Bombeli, T., Karsan, a., Tait, J.F., Harlan, J.M., Apoptotic vascular endothelial cells become procoagulant. Blood 89 (1997), 2429–2442, 10.1016/S0887-7963(97)80117-4.
72. [72] Farb, A., Burke, A.P., Tang, A.L., Liang, T.Y., Mannan, P., Smialek, J., et al. Coronary plaque erosion without rupture into a lipid core. A frequent cause of coronary thrombosis in sudden coronary death. Circulation 93 (1996), 1354–1363.
73. [73] Mallat, Z., Benamer, H., Hugel, B., Benessiano, J., Steg, P.G., Freyssinet, J.M., et al. Elevated levels of shed membrane microparticles with procoagulant potential in the peripheral circulating blood of patients with acute coronary syndromes. Circulation 101 (2000), 841–843, 10.1161/01.CIR.101.8.841.
74. [74] Martínez, M.C., Tesse, A., Zobairi, F., Andriantsitohaina, R., Shed membrane microparticles from circulating and vascular cells in regulating vascular function. Am J Physiol Heart Circ Physiol, 1004–9, 2005, 10.1152/ajpheart.00842.2004.
75. [75] Li, D., Yang, B., Mehta, J.L., Ox-LDL induces apoptosis in human coronary artery endothelial cells: role of PKC, PTK, bcl-2, and Fas. Am J Physiol 275 (1998), H568–H576.
76. [76] Sugano, M., Tsuchida, K., Makino, N., High-density lipoproteins protect endothelial cells from tumor necrosis factor-α-induced apoptosis. Biochem. Biophys. Res. Commun. 272 (2000), 872–876, 10.1006/bbrc.2000.2877.
77. [77] Nofer, J.-R., Levkau, B., Wolinska, I., Junker, R., Fobker, M., von Eckardstein, a., et al. Suppression of endothelial cell apoptosis by high density lipoproteins (HDL) and HDL-associated lysosphingolipids. J Biol Chem 276 (2001), 34480–34485, 10.1074/jbc.M103782200.
78. [78] Davì, G., Patrono, C., Mechanisms of disease: platelet activation and atherothrombosis. N. Engl. J. Med. 357 (2007), 2482–2494, 10.1056/NEJMra071014.
79. [79] Monaco, C., Mathur, A., Martin, J.F., What causes acute coronary syndromes? Applying Koch's postulates. Atherosclerosis 179 (2005), 1–15, 10.1016/j.atherosclerosis.2004.10.022.
80. [80] Bonaca, M.P., Steg, P.G., Feldman, L.J., Canales, J.F., Ferguson, J.J., Wallentin, L., et al. Antithrombotics in acute coronary syndromes. J. Am. Coll. Cardiol. 54 (2009), 969–984, 10.1016/j.jacc.2009.03.083.
81. [81] Martin, J.F., Kristensen, S.D., Mathur, A., Grove, E.L., Choudry, F.A., The causal role of megakaryocyte-platelet hyperactivity in acute coronary syndromes. Nat. Rev. Cardiol. 9 (2012), 658–670.
82. [82] Martin, J.F., Slater, D.N., Kishk, Y.T., Trowbridge, E.a., Platelet and megakaryocyte changes in cholesterol-induced experimental atherosclerosis. Arteriosclerosis 5 (2015), 604–612, 10.1161/01.ATV.5.6.604.
83. [83] Schick, B.P., Schick, P.K., The effect of hypercholesterolemia on guinea pig platelets, erythrocytes and megakaryocytes. Biochim. Biophys. Acta 833 (1985), 291–302.
84. [84] Pathansali, R., Smith, N., Bath, P., Altered megakaryocyte-platelet haemostatic axis in hypercholesterolaemia. Platelets 12 (2001), 292–297, 10.1080/09537100120058810.
85. [85] Martin, J.F., Plumb, J., Kilbey, R.S., Kishk, Y.T., Changes in volume and density of platelets in myocardial infarction. Br. Med. J. (Clin. Res. Ed.) 287 (1983), 456–459, 10.1136/bmj.287.6390.456.
86. [86] Cameron, H.a., Phillips, R., Ibbotson, R.M., Carson, P.H., Platelet size in myocardial infarction. Br. Med. J. (Clin. Res. Ed.) 287 (1983), 449–451, 10.1136/bmj.287.6390.449.
87. [87] Pizzulli, L., Yang, a., Martin, J.F., Lüderitz, B., Changes in platelet size and count in unstable angina compared to stable angina or non-cardiac chest pain. Eur. Heart J. 19 (1998), 80–84, 10.1053/euhj.1997.0747.
88. [88] Endler, G., Klimesch, A., Sunder-Plassmann, H., Schillinger, M., Exner, M., Mannhalter, C., et al. Mean platelet volume is an independent risk factor for myocardial infarction but not for coronary artery disease. Br. J. Haematol. 117 (2002), 399–404.
89. [89] Martin, J., Bath, P., Burr, M.L., Influence of platelet size on outcome after myocardial infarction. Lancet 338 (1991), 1409–1411 doi:0140-6736(91)92719-I [pii].
90. [90] Shattil, S.J., Anaya-Galindo, R., Bennett, J., Colman, R.W., Cooper, R.a., Platelet hypersensitivity induced by cholesterol incorporation. J. Clin. Invest. 55 (1975), 636–643, 10.1172/JCI107971.
91. [91] Hochgraf, E., Levy, Y., Aviram, M., Brook, J.G., Cogan, U., Lovastatin decreases plasma and platelet cholesterol levels and normalizes elevated platelet fluidity and aggregation in hypercholesterolemic patients., 1994 1994/01/01:11–7.
92. [92] Ravindran, R., Krishnan, L.K., Increased platelet cholesterol and decreased percentage volume of platelets as a secondary risk factor for coronary artery disease. Pathophysiol. Haemost. Thromb. 36 (2007), 45–51, 10.1159/000112639.
93. [93] Opper, C., Clement, C., Schwarz, H., Krappe, J., Steinmetz, a., Schneider, J., et al. Increased number of high sensitive platelets in hypercholesterolemia, cardiovascular diseases, and after incubation with cholesterol. Atherosclerosis 113 (1995), 211–217 doi:002191509405448R [pii].
94. [94] Betteridge, D.J., Cooper, M.B., Saggerson, E.D., Prichard, B.N., Tan, K.C., Ling, E., et al. Platelet function in patients with hypercholesterolaemia. Eur. J. Clin. Investig. 24:Suppl 1 (1994), 30–33.
95. [95] Sanguigni, V., Pignatelli, P., Caccese, D., Pulcinelli, F.M., Lenti, L., Magnaterra, R., et al. Increased superoxide anion production by platelets in hypercholesterolemic patients. Thromb. Haemost. 87 (2002), 796–801.
96. [96] Pawlowska, Z., Swiatkowska, M., Krzeslowska, J., Pawlicki, L., Cierniewski, C.S., Increased platelet-fibrinogen interaction in patients with hypercholesterolemia and hypertriglyceridemia. Atherosclerosis 103 (1993), 13–20.
97. [97] Garlichs, C.D., John, S., Schmeisser, A., Eskafi, S., Stumpf, C., Karl, M., et al. Upregulation of CD40 and CD40 ligand (CD154) in patients with moderate hypercholesterolemia. Circulation 104 (2001), 2395–2400.
98. [98] Cooper, M.B., Tan KCB. Platelet transmembrane signalling responses t o collagen in familial hypercholesterolaemia, 1994, 737–743.
99. [99] Bröijersén, a., Hamsten, a., Eriksson, M., Angelin, B., Hjemdahl, P., Platelet activity in vivo in hyperlipoproteinemia — importance of combined hyperlipidemia. Thromb. Haemost. 79 (1998), 268–275.
100. [100] Davì, G., Gresele, P., Violi, F., Basili, S., Catalano, M., Giammarresi, C., et al. Diabetes mellitus, hypercholesterolemia, and hypertension but not vascular disease per se are associated with persistent platelet activation in vivo: evidence derived from the study of peripheral arterial disease. Circ 96 (1997), 69–75, 10.1161/01.CIR.96.1.69.
101. [101] Huo, Y., Schober, A., Forlow, S.B., Smith, D.F., Hyman, M.C., Jung, S., et al. Circulating activated platelets exacerbate atherosclerosis in mice deficient in apolipoprotein E. Nat. Med. 9 (2002), 61–67, 10.1038/nm810.
102. [102] Surya, I.I., Mommersteeg, M., Gorter, G., Erkelens, D.W., Akkerman, J.W., Abnormal platelet functions in a patient with abetalipoproteinemia. Thromb. Haemost. 65 (1991), 306–311.
103. [103] Riddell, D.R., Graham, A., Owen, J.S., Apolipoprotein E inhibits platelet aggregation through the L-arginine:nitric oxide pathway: implications for vascular disease. J Biol Chem 272 (1997), 89–95, 10.1074/jbc.272.1.89.
104. [104] Higashihara, M., Kinoshita, M., Teramoto, T., Kume, S., Kurokawa, K., The role of apoE in inhibitory effects of apoE-rich HDL on platelet function. FEBS Lett. 282 (1991), 82–86 doi: http://dx.doi.org/10.1016/0014-5793(91)80449-D.
105. [105] Korporaal, S.J.a., J-WN, A., Platelet activation by low density lipoprotein and high density lipoprotein. Pathophysiol. Haemost. Thromb. 35 (2006), 270–280, 10.1159/000093220.
106. [106] Korporaal, S.J.A., Relou, I.a.M., van Eck, M., Strasser, V., Bezemer, M., Gorter, G., et al. Binding of low density lipoprotein to platelet apolipoprotein E receptor 2′ results in phosphorylation of p38 MAPK. J Biol Chem 279 (2004), 52526–52534, 10.1074/jbc.M407407200.
107. [107] Akkerman, J.W.N., From low-density lipoprotein to platelet activation. Int. J. Biochem. Cell Biol. 40 (2008), 2374–2378, 10.1016/j.biocel.2008.04.002.
108. [108] Assinger, A., Schmid, W., Eder, S., Schmid, D., Koller, E., Volf, I., Oxidation by hypochlorite converts protective HDL into a potent platelet agonist. FEBS Lett. 582 (2008), 778–784, 10.1016/j.febslet.2008.02.001.
109. [109] Podrez, E.a., Byzova, T.V., Febbraio, M., Salomon, R.G., Ma, Y., Valiyaveettil, M., et al. Platelet CD36 links hyperlipidemia, oxidant stress and a prothrombotic phenotype. Nat. Med. 13 (2007), 1086–1095, 10.1038/nm1626.
110. [110] Korporaal, S.J.A., van Eck, M., Adelmeijer, J., Ijsseldijk, M., Out, R., Lisman, T., et al. Platelet activation by oxidized low density lipoprotein is mediated by Cd36 and scavenger receptor-a. Arterioscler. Thromb. Vasc. Biol. 27 (2007), 2476–2483, 10.1161/ATVBAHA.107.150698.
111. [111] Nofer, J.R., Walter, M., Kehrel, B., Seedorf, U., Assmann, G., HDL3 activates phospholipase D in normal but not in glycoprotein IIb/IIIa-deficient platelets. Biochem. Biophys. Res. Commun. 207 (1995), 148–154 doi: http://dx.doi.org/10.1006/bbrc.1995.1165.
112. [112] Nazih, H., Nazih-Sanderson, F., Magret, V., Caron, B., Goudemand, J., Fruchart, J.C., et al. Protein kinase C-dependent desensitization of HDL3-activated phospholipase C in human platelets. Arterioscler. Thromb. Vasc. Biol. 14 (1994), 1321–1326, 10.1161/01.ATV.14.8.1321.
113. [113] Vergani, C.G., Plancher, A.C., Zuin, M., Cattaneo, M., Tramaloni, C., Maccari, S., et al. Bile lipid composition and haemostatic variables in a case of high density lipoprotein deficiency (Tangier disease). Eur. J. Clin. Investig. 14 (1984), 49–54.
114. [114] Naqvi, T.Z., Shah, P.K., Ivey, P.a., Molloy, M.D., Thomas, a.M., Panicker, S., et al. Evidence that high-density lipoprotein cholesterol is an independent predictor of acute platelet-dependent thrombus formation. Am. J. Cardiol. 84 (1999), 1011–1017.
115. [115] Brodde, M.F., Korporaal, S.J.a., Herminghaus, G., Fobker, M., TJC, V.B., UJF, T., et al. Native high-density lipoproteins inhibit platelet activation via scavenger receptor BI. Atherosclerosis 215 (2011), 374–382, 10.1016/j.atherosclerosis.2010.12.026.
116. [116] Weisgraber, K.H., Mahley, R.W., Subfractionation of human high density lipoproteins by heparin-sepharose affinity chromatography. J. Lipid Res. 21 (1980), 316–325.
117. [117] Ardlie, N.G., Selley, M.L., Simons, L.a., Platelet activation by oxidatively modified low density lipoproteins. Atherosclerosis 76 (1989), 117–124, 10.1016/0021-9150(89)90094-4.
118. [118] Desai, K., Bruckdorfer, K.R., Hutton, R.a., Owen, J.S., Binding of apoE-rich high density lipoprotein particles by saturable sites on human blood platelets inhibits agonist-induced platelet aggregation. J. Lipid Res. 30 (1989), 831–840.
119. [119] Aviram, M., Brook, J.G., The effect of blood constituents on platelet function: role of blood cells and plasma lipoproteins. Artery 11 (1983), 297–305.
120. [120] Aviram, M., Brook, J.G., Platelet interaction with high and low density lipoproteins. Atherosclerosis 46 (1983), 259–268 doi: http://dx.doi.org/10.1016/0021-9150(83)90176–4.
121. [121] Aviram, M., Sirtori, C.R., Colli, S., Maderna, P., Morazzoni, G., Tremoli, E., Plasma lipoproteins affect platelet malondialdehyde and thromboxane B2 production. Biomark. Med 34 (1985), 29–36 doi: http://dx.doi.org/10.1016/0006-2944(85)90059–6.
122. [122] Knorr, M., Locher, R., Vogt, E., Vetter, W., Block, L.H., Ferracin, F., et al. Rapid activation of human platelets by low concentrations of low-density lipoprotein via phosphatidylinositol cycle. Eur. J. Biochem. 172 (1988), 753–759, 10.1111/j.1432-1033.1988.tb13953.x.
123. [123] Mehta, J.L., Chen, L.Y., Reversal by high-density lipoprotein of the effect of oxidized low-density lipoprotein on nitric oxide synthase protein expression in human platelets. J Lab Clin Med 127 (1996), 287–295 doi: http://dx.doi.org/10.1016/S0022-2143(96)90097–9.
124. [124] Pedreno, J., Vila, M., Masana, L., Mechanisms for regulating platelet high density lipoprotein type3 binding sites: evidence that binding sites are downregulated by a protein kinase C-dependent mechanism. Thromb. Res. 94 (1999), 33–44 doi:S0049-3848(98)00196-0 [pii].
125. [125] Riddell, D.R., Vinogradov, D.V., Stannard, A.K., Chadwick, N., Owen, J.S., Identification and characterization of LRP8 (apoER2) in human blood platelets. J. Lipid Res. 40 (1999), 1925–1930.
126. [126] MacFarlane, R.G., An enzyme cascade in the blood clotting mechanism, and its function as a biochemical amplifier. Nature 202 (1964), 498–499.
127. [127] Davie, E.W., Ratnoff, O.D., Waterfall sequence for intrinsic blood clotting. Science 145 (1964), 1310–1312, 10.1126/science.145.3638.1310.
128. [128] Kawasaki, T., Kambayashi, J., Ariyoshi, H., Sakon, M., Suehisa, E., Monden, M., Hypercholesterolemia as a risk factor for deep-vein thrombosis. Thromb. Res. 88 (1997), 67–73.
129. [129] Kawasaki, T., Kambayashi, J., Sakon, M., Hyperlipidemia: a novel etiologic factor in deep vein thrombosis. Thromb. Res. 79 (1995), 147–151.
130. [130] Bradley, W.A., Gianturco, S.H., Vitamin K-dependent proteins bind to very low-density lipoproteins. Semin. Thromb. Hemost. 14 (1988), 253–257, 10.1055/s-2007-1002786.
131. [131] De Sousa, J.C., Soria, C., Ayrault-Jarrier, M., Pastier, D., Bruckert, E., Amiral, J., et al. Association between coagulation factors VII and X with triglyceride rich lipoproteins. J. Clin. Pathol. 41 (1988), 940–944.
132. [132] Silveira, A., Karpe, F., Blomback, M., Steiner, G., Walldius, G., Hamsten, A., Activation of coagulation factor VII during alimentary lipemia. Arterioscler Thromb a J Vasc Biol/Am Hear Assoc 14 (1994), 60–69.
133. [133] Moyer, M.P., Tracy, R.P., Tracy, P.B., van't Veer, C., Sparks, C.E., Mann, K.G., Plasma lipoproteins support prothrombinase and other procoagulant enzymatic complexes. Arterioscler. Thromb. Vasc. Biol. 18 (1998), 458–465.
134. [134] Rota, S., McWilliam, N.A., Baglin, T.P., Byrne, C.D., Atherogenic lipoproteins support assembly of the prothrombinase complex and thrombin generation: modulation by oxidation and vitamin E. Blood 91 (1998), 508–515.
135. [135] Xu, N., Ohlin, A.K., Zhou, L., Nilsson, A., Binding of prothrombin to chyle chylomicrons: effects of temperature and calcium ions, and role of surface phospholipids. Thromb. Res. 80 (1995), 35–46.
136. [136] Xu, N., Dahlback, B., Ohlin, A.K., Nilsson, A., Association of vitamin K-dependent coagulation proteins and C4b binding protein with triglyceride-rich lipoproteins of human plasma. Arterioscler. Thromb. Vasc. Biol. 18 (1998), 33–39.
137. [137] MacCallum, P.K., Cooper, J.A., Martin, J., Howarth, D.J., Meade, T.W., Miller, G.J., Haemostatic and lipid determinants of prothrombin fragment F1.2 and D-dimer in plasma. Thromb. Haemost. 83 (2000), 421–426.
138. [138] Mackman, N., Tilley, R.E., Key, N.S., Role of the extrinsic pathway of blood coagulation in hemostasis and thrombosis. Arterioscler. Thromb. Vasc. Biol. 27 (2007), 1687–1693, 10.1161/ATVBAHA.107.141911.
139. [139] Wilcox, J.N., Smith, K.M., Schwartz, S.M., Gordon, D., Localization of tissue factor in the normal vessel wall and in the atherosclerotic plaque. Proc. Natl. Acad. Sci. U. S. A. 86 (1989), 2839–2843.
140. [140] Drake, T.A., Hannani, K., Fei, H.H., Lavi, S., Berliner, J.A., Minimally oxidized low-density lipoprotein induces tissue factor expression in cultured human endothelial cells. Am J Pathol 138 (1991), 601–607.
141. [141] Carson, S.D., Plasma high density lipoproteins inhibit the activation of coagulation factor X by factor VIIa and tissue factor. FEBS Lett. 132 (1981), 37–40 doi: http://dx.doi.org/10.1016/0014-5793(81)80422-X.
142. [142] Carson, S.D., Ross, S.E., Effects of lipid-binding proteins apo A-I, apo A-IL, beta 2-glycoprotein I, and C-reactive protein on activation of factor X by tissue factor–factor VIIa. Thromb. Res. 50 (1988), 669–678.
143. [143] Lowe, G.D., Drummond, M.M., Third, J.L., Bremner, W.F., Forbes, C.D., Prentice, C.R., et al. Increased plasma fibrinogen and platelet-aggregates in type II hyperlipoproteinaemia. Thromb. Haemost. 42 (1980), 1503–1507.
144. [144] DiMinno, G., Silver, M.J., Cerbone, A.M., Rainone, A., Postiglione, A., Mancini, M., Increased fibrinogen binding to platelets from patients with familial hypercholesterolemia. Arterioscler. Thromb. Vasc. Biol. 6 (1986), 203–211, 10.1161/01.ATV.6.2.203.
145. [145] Cremer, P., Nagel, D., Labrot, B., Mann, H., Muche, R., Elster, H., et al. Lipoprotein Lp(a) as predictor of myocardial infarction in comparison to fibrinogen, LDL cholesterol and other risk factors: results from the prospective Göttingen Risk Incidence and Prevalence Study (GRIPS). Eur. J. Clin. Investig. 24 (1994), 444–453, 10.1111/j.1365-2362.1994.tb02373.x.
146. [146] Koenig, W., Sund, M., Ernst, E., Mraz, W., Hombach, V., Keil, U., Association between rheology and components of lipoproteins in human blood. Results from the MONICA project. Circ 85 (1992), 2197–2204, 10.1161/01.CIR.85.6.2197.
147. [147] Halle, M., Berg, A., Keul, J., Baumstark, M.W., Association between serum fibrinogen concentrations and HDL and LDL subfraction phenotypes in healthy men. Arterioscler. Thromb. Vasc. Biol. 16 (1996), 144–148, 10.1161/01.ATV.16.1.144.
148. [148] Møller, L., Kristensen, T.S., Plasma fibrinogen and ischemic heart disease risk factors. Arterioscler. Thromb. Vasc. Biol. 11 (1991), 344–350, 10.1161/01.ATV.11.2.344.
149. [149] Griffin, J.H., Kojima, K., Banka, C.L., Curtiss, L.K., Fernandez, J.A., High-density lipoprotein enhancement of anticoagulant activities of plasma protein S and activated protein C. J. Clin. Invest. 103 (1999), 219–227, 10.1172/JCI5006.
150. [150] Griffin, J.H., Fernández, J.A., Deguchi, H., Plasma lipoproteins, hemostasis and thrombosis. Thromb. Haemost. 86 (2001), 386–394.
151. [151] Oslakovic, C., Norstrøm, E., Dahlbäck, B., Reevaluation of the role of HDL in the anticoagulant activated protein C system in humans. J. Clin. Invest. 120 (2010), 1396–1399, 10.1172/JCI42260.
152. [152] Fernandez, J.a., Deguchi, H., Banka, C.L., Witztum, J.L., Griffin, J.H., Re-evaluation of the anticoagulant properties of high-density lipoprotein—brief report. Arterioscler. Thromb. Vasc. Biol. 35 (2015), 570–572, 10.1161/ATVBAHA.114.304938.
153. [153] Rosenson, R.S., Lowe, G.D.O., Effects of lipids and lipoproteins on thrombosis and rheology. Atherosclerosis 140 (1998), 271–280 doi: http://dx.doi.org/10.1016/S0021-9150(98)00144–0.
154. [154] Szczeklik, A., Musial, J., Undas, A., Gajewski, P., Gora, P., Swadzba, J., et al. Inhibition of thrombin generation by simvastatin and lack of additive effects of aspirin in patients with marked hypercholesterolemia. J. Am. Coll. Cardiol. 33 (1999), 1286–1293.
155. [155] Stroes, E., Statins and LDL-cholesterol lowering: an overview. Curr. Med. Res. Opin. 21 (2005), S9–16, 10.1185/030079905X59102.
156. [156] Seidah, N.G., Benjannet, S., Wickham, L., Marcinkiewicz, J., Jasmin, S.B., Stifani, S., et al. The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): liver regeneration and neuronal differentiation. Proc. Natl. Acad. Sci. U. S. A. 100 (2003), 928–933, 10.1073/pnas.0335507100.
157. [157] Sabatine, M.S., Giugliano, R.P., Wiviott, S.D., Raal, F.J., Blom, D.J., Robinson, J., et al. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N. Engl. J. Med. 372 (2015), 1500–1509, 10.1056/NEJMoa1500858.
158. [158] Robinson, J.G., Farnier, M., Krempf, M., Bergeron, J., Luc, G., Averna, M., et al. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N. Engl. J. Med. 372 (2015), 1489–1499, 10.1056/NEJMoa1501031.
159. [159] Shimada, Y.J., Cannon, C.P., PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitors: past, present, and the future. Eur. Heart J. 36 (2015), 2415–2424, 10.1093/eurheartj/ehv174.
160. [160] Li, S., Zhu, C., Guo, Y., Xu, R., Zhang, Y., Sun, J., et al. The relationship between the plasma PCSK9 levels and platelet. 2015, 76–84.
161. [161] Thaulow, E., Erikssen, J., Sandvik, L., Stormorken, H., Cohn, P.F., Blood platelet count and function are related to total and cardiovascular death in apparently healthy men. Circulation 84 (1991), 613–617, 10.1161/01.CIR.84.2.613.
162. [162] Duivenvoorden, R., Fayad, Z.a., Safety of CETP inhibition. Curr. Opin. Lipidol. 23 (2012), 518–524, 10.1097/MOL.0b013e32835916b3.
163. [163] Schwartz, G.G., Olsson, A.G., Abt, M., Ballantyne, C.M., Barter, P.J., Brumm, J., et al. Effects of dalcetrapib in patients with a recent acute coronary syndrome. N. Engl. J. Med. 367 (2012), 2089–2099, 10.1056/NEJMoa1206797.
164. [164] Tardif, J.-C., Rheaume, E., Lemieux Perreault, L.-P., Gregoire, J.C., Feroz Zada, Y., Asselin, G., et al. Pharmacogenomic determinants of the cardiovascular effects of dalcetrapib. Circ Cardiovasc Genet 8 (2015), 372–382, 10.1161/CIRCGENETICS.114.000663.
165. [165] Niesor, E.J., Benghozi, R., Potential signal transduction regulation by HDL of the β2-adrenergic receptor pathway. Implications in selected pathological situations. Arch. Med. Res. 46 (2015), 361–371, 10.1016/j.arcmed.2015.05.008.
166. [166] Krause, B.R., Remaley, A.T., Reconstituted HDL for the acute treatment of acute coronary syndrome. Curr. Opin. Lipidol. 24 (2013), 480–486, 10.1097/MOL.0000000000000020.
167. [167] Lerch, P.G., Spycher, M.O., Doran, J.E., Reconstituted high density lipoprotein (rHDL) modulates platelet activity in vitro and ex vivo. Thromb. Haemost. 80 (1998), 316–320 doi:98080316 [pii].
168. [168] Li, D., Weng, S., Yang, B., Zander, D.S., Saldeen, T., Nichols, W.W., et al. Inhibition of arterial thrombus formation by ApoA1 Milano. Arterioscler. Thromb. Vasc. Biol. 19 (1999), 378–383, 10.1161/01.ATV.19.2.378.
169. [169] Calkin, A.C., Drew, B.G., Ono, A., Duffy, S.J., Gordon, M.V., Schoenwaelder, S.M., et al. Reconstituted high-density lipoprotein attenuates platelet function in individuals with type 2 diabetes mellitus by promoting cholesterol efflux. Circ 120 (2009), 2095–2104, 10.1161/CIRCULATIONAHA.109.870709.
170. [170] Pajkrt, D., Lerch, P.G., van der Poll, T., Levi, M., Illi, M., Doran, J.E., et al. Differential effects of reconstituted high-density lipoprotein on coagulation, fibrinolysis and platelet activation during human endotoxemia. Thromb. Haemost. 77 (1997), 303–307.
171. [171] Chawla, A., Repa, J.J., Evans, R.M., Mangelsdorf, D.J., Nuclear receptors and lipid physiology: opening the X-files. Sci 294 (2001), 1866–1870, 10.1126/science.294.5548.1866.
172. [172] Joseph, S.B., Castrillo, A., Laffitte, B.a., Mangelsdorf, D.J., Tontonoz, P., Reciprocal regulation of inflammation and lipid metabolism by liver X receptors. Nat. Med. 9 (2003), 213–219, 10.1038/nm820.
173. [173] Joseph, S.B., McKilligin, E., Pei, L., Watson, M.A., Collins, A.R., Laffitte, B.A., et al. Synthetic LXR ligand inhibits the development of atherosclerosis in mice. Proc. Natl. Acad. Sci. U. S. A. 99 (2002), 7604–7609, 10.1073/pnas.112059299.
174. [174] Tangirala, R.K., Bischoff, E.D., Joseph, S.B., Wagner, B.L., Walczak, R., Laffitte, B.A., et al. Identification of macrophage liver X receptors as inhibitors of atherosclerosis. Proc. Natl. Acad. Sci. 99 (2002), 11896–11901, 10.1073/pnas.182199799.
175. [175] Spyridon, M., Moraes, L.A., Jones, C.I., Sage, T., Sasikumar, P., Bucci, G., et al. LXR as a novel antithrombotic target. Blood 117 (2011), 5751–5761, 10.1182/blood-2010-09-306142.
176. [176] Calkin, A.C., Tontonoz, P., Transcriptional integration of metabolism by the nuclear sterol-activated receptors LXR and FXR. Nat. Rev. Mol. Cell Biol. 13 (2012), 213–224, 10.1038/nrm3312.
177. [177] Peet, D.J., Turley, S.D., Ma, W., Janowski, B.a., Lobaccaro, J.M.a., Hammer, R.E., et al. Cholesterol and bile acid metabolism are impaired in mice lacking the nuclear oxysterol receptor LXRα. Cell 93 (1998), 693–704, 10.1016/S0092-8674(00)81432-4.
178. [178] Alberti, S., Schuster, G., Parini, P., Feltkamp, D., Diczfalusy, U., Rudling, M., et al. Hepatic cholesterol metabolism and resistance to dietary cholesterol in LXRβ-deficient mice. J. Clin. Invest. 107 (2001), 565–573, 10.1172/JCI9794.
179. [179] McGeehan, G.M., Lala, D.S., Zhao, Y., Noto, P.B., Zhuang, L., Claremon, D.A., et al. Abstract 334: the LXRβ selective agonist, VTP-38443, significantly decreases plaque cholesterol ester content and inflammation in a murine model of accelerated atherosclerosis. Arterioscler. Thromb. Vasc. Biol., 35, 2015 A334–A334.